Therapeutic Response

ER negative, HER2-negative, PD-L1 >= 1%, and PR negative status confers therapeutic sensitivity to Atezolizumab in combination with Nab-paclitaxel in patients with Invasive Breast Carcinoma.

Statements

Source and description

Tecentriq (atezolizumab) [product monograph]. HC. Health Canada approved atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering >= 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.